CA2642572A1 - Plasma de patients atteints de vitiligo pour le traitement d'un melanome - Google Patents

Plasma de patients atteints de vitiligo pour le traitement d'un melanome Download PDF

Info

Publication number
CA2642572A1
CA2642572A1 CA002642572A CA2642572A CA2642572A1 CA 2642572 A1 CA2642572 A1 CA 2642572A1 CA 002642572 A CA002642572 A CA 002642572A CA 2642572 A CA2642572 A CA 2642572A CA 2642572 A1 CA2642572 A1 CA 2642572A1
Authority
CA
Canada
Prior art keywords
melanoma
vitiligo
patient
composition
plasma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002642572A
Other languages
English (en)
Inventor
Yehuda Shoenfeld
Pnina Fishman
Jacob Nusbacher
Vered Kaplan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GAMMACAN Ltd
Original Assignee
GAMMACAN Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GAMMACAN Ltd filed Critical GAMMACAN Ltd
Publication of CA2642572A1 publication Critical patent/CA2642572A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002642572A 2006-02-15 2007-02-15 Plasma de patients atteints de vitiligo pour le traitement d'un melanome Abandoned CA2642572A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US77333506P 2006-02-15 2006-02-15
US60/773,335 2006-02-15
PCT/US2007/003919 WO2007095293A2 (fr) 2006-02-15 2007-02-15 PLASMA de patients atteints de vitiligo pour le traitement d'un melanome

Publications (1)

Publication Number Publication Date
CA2642572A1 true CA2642572A1 (fr) 2007-08-23

Family

ID=38372113

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002642572A Abandoned CA2642572A1 (fr) 2006-02-15 2007-02-15 Plasma de patients atteints de vitiligo pour le traitement d'un melanome

Country Status (2)

Country Link
CA (1) CA2642572A1 (fr)
WO (1) WO2007095293A2 (fr)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731325A (en) * 1995-06-06 1998-03-24 Andrulis Pharmaceuticals Corp. Treatment of melanomas with thalidomide alone or in combination with other anti-melanoma agents

Also Published As

Publication number Publication date
WO2007095293A2 (fr) 2007-08-23
WO2007095293A3 (fr) 2008-04-24

Similar Documents

Publication Publication Date Title
JP6656349B2 (ja) 単純ヘルペスウイルスおよび免疫チェックポイント阻害薬を使用して、メラノーマを治療するための方法
US20080008716A1 (en) Combined Pharmaceutical Composition Comprising an Anti-4-1BB Monoclonal Antibody and Chemotherapeutic Anti-Cancer Agent for Preventing and Treating Cancer Disease
JP6941321B2 (ja) 疾患の要因となる生体内タンパク質を標的とするコンジュゲートワクチン
BR112016011499A2 (pt) uso de uma composição compreendendo um inibidor da proteína c1-esterase (c1-inh), composição farmacêutica compreendendo o mesmo e seus kits
Ludvigsson Therapies to preserve β-cell function in type 1 diabetes
WO2016034081A1 (fr) Méthodes et compositions de traitement de cancers associés à c-met
KR20130066626A (ko) 항ｃｄ3 면역 분자 요법을 사용하여 간염을 치료하는 방법 및 이를 위한 조성물
BR112021003093A2 (pt) tratamento de câncer de mama triplo negativo que visa a inibição de tgf-beta
Sato et al. Efficacy of repeated lusutrombopag administration for thrombocytopenia in a patient scheduled for invasive hepatocellular carcinoma treatment
US20130177548A1 (en) Treating neoplasms with neurotoxin
BR112020007731A2 (pt) composição farmacêutica para o tratamento de linfoma de células b, uso do obinutuzumabe e método para tratar o linfoma de células b cd20-positivo
CA2642572A1 (fr) Plasma de patients atteints de vitiligo pour le traitement d'un melanome
US20230173049A1 (en) Fusion proteins and methods of use thereof
US20230065168A1 (en) Vismodegib in combination with a replication-deficient type 5 adenovirus for expression of interferon gamma for the treatment of skin cancer
WO2017202227A1 (fr) Application de z-butylidènephtalide permettant de revigorer le système immunitaire inné
JP2017109987A (ja) ＥｒｂＢ４＋炎症性マクロファージによって媒介される疾患の治療方法
AU2009319732B2 (en) Treating neoplasms with neurotoxin
AU2007237163A1 (en) Immunoglobulins from vitiligo plasma for melanoma therapy
CA2882553A1 (fr) Preparation pour la prevention ou le traitement du diabete de type 1
JPWO2003020306A1 (ja) 脱感作剤
Lu et al. Report of 2 cases of glucagonoma syndrome with a brief review of literature
AU2016202748A1 (en) Treating neoplasms with neurotoxin
AU2013213713A1 (en) Treating neoplasms with neurotoxin
EA044256B1 (ru) Способ лечения меланомы с применением вируса простого герпеса и ингибитора иммунной контрольной точки

Legal Events

Date Code Title Description
FZDE Discontinued